Advanced in Leukemia

Stephan K. Metzelder

Marburg An Der Lahn, HE, DE 
Advanced in Leukemia
Marburg An Der Lahn, HE, DE 
OverviewLocationsClinical Research

Overview

Stephan Metzelder practices in Marburg An Der Lahn, Germany. Mr. Metzelder is rated as an Advanced expert by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Chronic Myelogenous Leukemia (CML), and Bone Marrow Transplant.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 15 articles and participated in 1 clinical trial in the study of Leukemia.

Gender
Male

Locations

Marburg An Der Lahn, HE, Germany
Other Locations
Giessen, HE, Germany
Aachen, NW 52074, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker
Enrollment Status: Terminated
Publish Date: July 10, 2023
Intervention Type: Drug
Study Drug: GEM3PSCA
Study Phase: Phase 1
View 1 Less Clinical Trial

21 Total Publications

Malnutrition in Cancer Patients - An Investigation of Malnutrition and Professional Intervention by Healthcare Professionals in Oncology.
Malnutrition in Cancer Patients - An Investigation of Malnutrition and Professional Intervention by Healthcare Professionals in Oncology.
Journal: In vivo (Athens, Greece)
Published: June 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Metzelder's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile